Drugs and Family Medicine: Form and Content

Jose Luis Turabian*

Specialist in Family and Community Medicine, Health Center Santa María de Benquerencia. Regional Health Service of Castilla la Mancha (SESCAM), Toledo, Spain

*Correspondence should be addressed to Jose Luis Turabian; jturabianf@hotmail.com

Received date: August 24, 2020, Accepted date: September 15, 2020

Copyright: © 2020 Turabian JL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Choosing an individual medication for a particular patient is one of the most important clinical decisions in family medicine (FM). Prescription of drugs is currently the main tool of FM and that’s the main source of prescription of drugs. The drugs are used by general practitioners (GPs) to manage a wide range of health problems that are addressed at this level of medical care have tangible results. But should the drug be the GP’s main therapeutic resource? Drugs arrive to serve the purposes of the GP, but finally, the GP redefines its own goals according to the drugs. Prescription rates have increased and polypharmacy is very frequent, a new doctor-patient relationship has appeared: a “patient-drug relationship” where the GP is excluded, there is an increase iniatrogenesis because of high rate of adverse drug reactions and drug-drug-interactions, and the importance of the non-pharmacological aspects of the medication is completely forgotten. In the matter of drugs on FM it is necessary to take into account the opposition and relationship between “the content and the form.” The “content” is not in the drugs; it is in conceptual foundations of FM and the GP must not forget the crucial elements on which his/her work is based: the use of a special clinical interview, continuity of care, knowledge of the context for the diagnosis and treatment, the wise use of drugs and technologies, and a permanent ability to critically reflect on the situation presented in the consultation.

Keywords: Drug utilization, Prescription drugs, Pharmaceutical treatment, Family practice, General practice, Polypharmacy, Drug interactions, Inappropriate prescribing, Prescribing influences, Physician-patient relations, Framework

Prescription of drugs is currently the main tool of family medicine (FM) and that’s the main source of prescription of drugs. More than 75 percent of all visits to family physicians/general practitioners (GPs) result in the prescription of at least one medication [1]. The drugs are used by GPs to manage a wide range of health problems that are addressed at this level of medical care: bacterial infections, chronic diseases such as diabetes, hypertension, coronary heart disease, bronchial asthma, COPD, depression/anxiety, etc, as well as other daily needs such as contraception. On the other hand, innovative pharmacological therapies, such as new treatments for cancer, HIV/AIDS, vaccines or hepatitis C, also are directly or indirectly used by GPs. All of these drugs have tangible results: in some cases, they manage to eradicate a disease, and in others, to control it better, increase hope life or reduce the side effects of previous therapies.

But should the drug be the GP’s main therapeutic resource? The ease and speed of incorporation and use of new drugs, the ease of maintaining and repeating legacy drug-prescribing patterns, and the resistance to abandonment of drugs of dubious efficacy by the GPs are striking [2,3].

Pharmacological advances have favored a mechanistic and medicalizing approach to health; with the advancement of biochemistry, success has been achieved in many medical interventions, as long as the problem is reduced to a biochemical phenomenon. An example of this “reductionist” approach is depression (it is a deficiency of serotonin) and we have a drug to act in the opposite direction (the selective serotonin reuptake inhibitor drugs).

In addition, prescription rates have increased, among other causes, due to the greater availability of effective medications, changes in patient expectations, and the
A New Doctor-patient Relationship

The probabilities of success in a treatment are directly proportional to the equality of the doctor-patient relationship. Thus, it is essential to know the pharmacology of the drugs used, but also the non-pharmacological aspects of these, such as non-specific adverse effects (nocebo), the placebo effect, non-compliance, cost, psychological meanings, ethical aspects, etc. In the use of drugs, the aspect related to pharmacology changes doctor-patient relationship: the effect that the doctor is the more important drug itself disappears [14,15]. The drug imposes a new doctor-patient relationship: the priority is for pharmacological chemical product (the drug), and the doctor-patient relationship becomes exclusively a pharmacological relationship: a “patient-drug relationship” where the GP is excluded [16-18].

An Increase in Yatrogenesis

There is an epidemic of diagnoses and treatments. The prevalence of the disease is growing rapidly in societies with high-tech medicine [19,20]. In this way, there is a “creation of new diseases”, which result in giving pharmacological treatments for minor problems, the concern about future diseases in healthy populations is increased, and personal and social problems are converted into diagnosable health disorders and in need of drug treatment [21]. Multimorbidity, in a small but significant part, is created by the medical intervention itself [22]. So, polypharmacy appears. But polypharmacy does not depend exclusively on the multimorbidity; the main cause of polypharmacy (of excessive use of drugs) is the professional in itself. It is admitted that the prevalence general of polypharmacy is high, and could reach 20% (23-25). However, the presence of polypharmacy is an indicator of malpractice and poor quality of the FM: polypharmacy originates a series of facts that lead to medical malpractice, and this is a cumulative process [23,26].

One common consequence of polypharmacy is the high rate of adverse drug reactions (ADRs). Many ADRs are due to drug-drug-interactions (DDIs). The risk of a DDI in any particular patient increases with the number of co-existing diseases and the number of drugs prescribed. It should be noted that the frequency of ADRs is 6% when a patient takes two medications, 50% when he takes five and almost 100% when he takes eight or more medications [27,28]. ADRs complicate up to 20% of therapeutic drug courses [29].

In summary, choosing an individual medication for a particular patient is one of the most important clinical decisions in FM. Doctor’s prescription decision is the result of the patient’s contribution, commercial sources; professional colleagues, academic literature, lines of research, etc. [3,30-34].

In the matter of drugs on FM it is necessary to take into account the opposition and relationship between “the content and the form.” Content is the main question, the essential, the conceptual basis, what underlies and survives more or less intact to external contingencies, that whose existence is presupposed but not seen. The form is the more or less contingent aspect, changing and adaptable to the circumstances that surround the fund; the ostensible manifestation of the form is by definition mutable. Thus, it is not only or mainly about attending to the “form”: for example, the need for GPs training to make
precise decisions regarding new powerful and expensive drugs [7]. But it should also be borne in mind that drug training in general is oriented towards the description of its pharmacological characteristics without taking into account others that modify the doctor-patient encounter and may condition a change in attitude in the prescriptions of daily practice. Likewise, it is necessary to be aware that drug regimens are increasingly complex and potentially harmful [35], and GPs need to regularly review and optimize chronic medication [36] and clinical guidelines should also consider making recommendations on when to stop medications [35,37,38].

Real “content” of the matter of the drugs on FM is not in the drugs; it is in conceptual foundations of FM; it is that the GP must not forget the crucial elements on which his/her work is based: the use of a special clinical interview, continuity of care, knowledge of the context for the diagnosis and treatment, the wise use of drugs and technologies, and a permanent ability to critically reflect on the situation presented in the consultation [39].

References

1. Cypress BK. Drug utilization in general and family practice by characteristics of physicians and office visits: National Ambulatory Medical Care Survey, 1980. Advance Data. 1983 Mar 28;(87):1-12.

2. Mangin D, Lawson J, Cuppage J, Shaw E, Ivanyi K, Davis A, Risdon C. Legacy drug-prescribing patterns in primary care. The Annals of Family Medicine. 2018 Nov 1;16(6):515-20.

3. Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs—the importance of who says what. Family Practice. 2003 Feb 1;20(1):61-8.

4. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Medicine. 2015 Dec 1;13(1):74.

5. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. The American journal of medicine. 1982 Jul 1;73(1):4-8.

6. McDonald CJ. Protocol-based computer reminders, the quality of care and the non-perfectibility of man. New England Journal of Medicine. 1976 Dec 9;295(24):1351-5.

7. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. The Milbank Quarterly. 1989 Jan 1;268-317.

8. Conrad P. The meaning of medications: another look at compliance. Social Science & Medicine. 1985 Jan 1;20(1):29-37.

9. Turabian JL. The Importance of the Placebo Effect in the Treatment of Different Diseases: A Vision From General Medicine. COJ Reviews & Research. 2019;2(1): COJRR.000529.2019.

10. Turabian JL. The placebo effect from the biopsychosocial perspective of general medicine: Non-effective interventions that are, in fact, effective. International Journal of Family & Community Medicine. 2019;3(1):16-21.

11. Turabian JL (2020) Transference and countertransference are linked to placebo-nocebo effects and they are an auxiliary resource of unparalleled value in general medicine: Recommendations for general practitioners. Archives of Psychiatry and Mental Health. 2020 Feb 27;4:001-006.

12. Turabian JL, Perez Franco B. [The concept of treatment in family medicine: A contextualised and contextual map of a city hardly seen]. [Article in Spanish]. Atencion primaria. 2010 Mar 7;42(5):253-4.

13. Turabian JL, Perez Franco B. [Prescription of Medication by Family Doctors: Rational, Reason, or Relevant?]. [Article in Spanish]. Aten primaria. 2005 Nov;36(9):507-9.

14. Turabián JL, Franco BP. Impact of the induced prescription on the doctor-patient relationship. Revista de calidad asistencial: organo de la Sociedad Espanola de Calidad Asistencial. 2011;26(1):67-9.

15. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002 Feb 6;287(5):622-7.

16. Turabian JL. Drug Prescription Modifies the Doctor-Patient Relationship in General Medicine. Archives of Family Medicine and General Practice Archives of Family Medicine and General Practice Archives of Family Medicine and General Practice. 2018;3(1):66-9.

17. Turabian JL. The wrong transformation of doctor-patient relationship in drug-patient relationship: From the doctor himself as a drug to doctor as drug dealer. Chronicle of Medicine and Surgery. 2018;3(1):298-301.
18. Balint M. Treatment or diagnosis. A study of repeated prescriptions in general practice. London: Tavistock. 1984.

19. Sen A. Health: perception versus observation. BMJ. 2002 Apr 13; 324(7342): 860-1.

20. Illich I, Cerella A. The obsession with perfect health. Journal for Cultural Research. 2017 Jul 3;21(3):286-91.

21. Moynihan R, Brodersen J, Heath I, Johansson M, Kuehlein T, Minué-Lorenzo S, et al. Reforming disease definitions: a new primary care led, people-centred approach. BMJ Evidence-based Medicine. 2019 Oct 1;24(5):170-3.

22.-Turabian JL. Theory of the Evolution of Multimorbidity: It is Created, In A Small Part but Significant, by the Medical Intervention Itself. COJ Reviews & Research. 2020 Feb 10;2(3): COJRR.000540.

23. Turabian JL. Polypharmacy is an Indicator of Bad Practice and Low Quality in General Medicine. Journal of Quality in Health Care & Economics. 2019 May 07;2(4): 000130.

24. Turabian JL, Pérez Franco B. [A way of helping "Mr. Minotaur" and "Ms. Ariadne" to exit from the multiple morbidity labyrinth: the “master problems”). [Article in Spanish]. Semergen. 2016 Feb;42(1):38-48.

25. Turabian JL. Notes for a Theory of Multimorbidity in General Medicine: The Problem of Multimorbidity Care is Not in Practice, but in the Lack of Theoretical Conceptualization. Journal of Public Health and General Medicine. 2018;1(1):1-7.

26. Turabian JL. Hypothesis and Practices to Avoid Polypharmacy in Family Medicine. MedRead Journal of Family Medicine. 2020 Jan09;1(1):1001.

27. Rodríguez del Río E, Martínez Agüero M, Arias Fernández L, Martín-Sánchez FJ. [Global intervention in the polymedicated patient]. [Article in Spanish]. Gaceta Sanitaria. 2016 Oct;30(5):402.

28. Turabian JL, Perez Franco B. Helping “Dr. Theseus” Leaves the Labyrinth of Multiple Drug Interactions. BMJ. 2015;350:h1059.

29. Pourpak Z, Fazollahi MR, Fattahi F. Understanding adverse drug reactions and drug allergies: principles, diagnosis and treatment aspects. Recent Patents on Inflammation & Allergy Drug Discovery. 2008 Jan 1;2(1):24-46.

30. Expósito Hernández J. [The problem of decisions in oncology]. [Article in Spanish]. AREA 3. CUENAS DE TEMAS GRUPALES E INSTITUCIONALES. 1995.

31. Comaroff J. A bitter pill to swallow: placebo therapy in general practice. The Sociological Review. 1976 Feb;24(1):79-96.

32. Marsh GN. “Curing” minor illness in general practice. British Medical Journal. 1977 Nov 12;2(6097):1267-9.

33. Georgopoulos BS, Coleman JS, Katz E, Menzel H. Medical innovation: A diffusion study. Indianapolis: The Bobbs-Merrill Company, 1966. Syst Res; 12: 481-3.

34. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. The New England Journal of Medicine; 1987 Aug 27;317(9):550-6.

35. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age and Ageing. 2013 Jan 1;42(1):62-9.

36. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012 Jul 7;380(9836):37-43.

37. Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ. 2012 Oct 4;345:e6341.

38. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005 Aug 10;294(6):716-24.

39. Turabian JL, Franco BP. [Reflections on the present and future of family medicine]. [Article in Spanish]. Gaceta Sanitaria. 2013;28(3):259.